File(s) under permanent embargo

Minocycline as adjunctive treatment for major depressive disorder: Pooled data from two randomized controlled trials

journal contribution
posted on 2021-08-01, 00:00 authored by R Zazula, M I Husain, Mohammadreza MohebbiMohammadreza Mohebbi, Adam WalkerAdam Walker, I B Chaudhry, A B Khoso, Melanie AshtonMelanie Ashton, B Agustini, N Husain, J F W Deakin, A H Young, Michael BerkMichael Berk, B Kanchanatawan, C H Ng, Michael Maes, Lesley BerkLesley Berk, Ajeet SinghAjeet Singh, G S Malhi, Olivia DeanOlivia Dean
Background: Randomized controlled clinical trials that have investigated minocycline as an adjunctive treatment for major depressive disorder have proved promising. Data from two studies were pooled to evaluate more definitively whether the addition of minocycline to standard treatment for major depressive disorder leads to an improvement of depressive symptoms when compared with placebo. Methods: Both studies were multi-site, double-blinded, placebo-controlled trials of minocycline 200 mg/day added to treatment as usual during a 12-week period. The primary outcome measure was change in depressive symptoms (Montgomery–Asberg Depression Rating Scale in Dean et al. and Hamilton Depression Rating Scale in Husain et al.). Secondary outcomes were change in depression severity (Montgomery–Asberg Depression Rating Scale for Dean et al. and 9-item Patient Health Questionnaire in Husain et al.), anxiety severity (Hamilton Anxiety Rating Scale in Dean et al. and Generalized Anxiety Disorder 7-item scale in Husain et al.) and functional status, which were also evaluated as potential mediators on the primary outcome. Results: A total of 112 participants were included in the pooled data (Dean et al., n = 71; Husain et al., n = 41). A significant change from baseline to week 12 was noted in depressive symptoms – differential change (Placebo vs Minocycline): 9.0, 95% confidence interval = [4.2, 13.9], Cohen’s D (95% confidence interval): 0.71 [0.29, 1.14], p < 0.001 – anxiety severity – differential change (Placebo vs Minocycline): 0.38, confidence interval = [0.00, 0.75], Cohen’s D (95% confidence interval): 0.41 [0.00, 0.82], p = 0.050) and functional status – differential change (Placebo vs Minocycline): 1.0, 95% confidence interval = [0.4, 1.5], Cohen’s D (95% confidence interval): 0.76 [0.34, 1.19], p = 0.001). Duration of illness, current use of benzodiazepine and pain medication were identified as moderators, whereas functional status as a mediator/predictor. Conclusion: The improvement of depressive symptoms, anxiety severity and functional status is promising and suggests that minocycline has potential as an adjunctive treatment for major depressive disorder. However, further studies are warranted to confirm therapeutic effects of minocycline in major depressive disorder. Trial registrations: NCT02263872, registered October 2014, and ACTRN12612000283875, registered March 2012.

History

Journal

Australian and New Zealand Journal of Psychiatry

Volume

55

Issue

8

Article number

ARTN 0004867420965697

Pagination

784 - 798

Publisher

SAGE PUBLICATIONS LTD

Location

England

ISSN

0004-8674

eISSN

1440-1614

Language

English

Publication classification

C1 Refereed article in a scholarly journal